A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]: NATALEE)

  • Sabanathan, Dhanusha (Primary Chief Investigator)
  • Kefford, Richard (Chief Investigator)
  • Cunningham, Jacob (Research Coordinator)

Project: Other

Project Details

StatusActive
Effective start/end date21/03/19 → 20/03/24